ClinicalTrials.gg
Active, not recruitingNCT05563844Updated Feb 4, 2026

Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

A Phase 2 interventional study of PM 8.4 mg/m^2 and PM 11.2 mg/m^2 in Diffuse Large B Cell Lymphoma,DLBCL, sponsored by Chengdu Zenitar Biomedical Technology Co., Ltd. Active, not recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by Chengdu Zenitar Biomedical Technology Co., Ltd · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Purinostat mesylate for injection (PM) was the novel and highly potent Class Ia and IIb HDAC selective inhibitor. The results of regular blood sampling analysis of the mouse B-cell lymphoma model induced by ighmyc transgenic mice showed that the treatment of PM in each group reduced the proportion of peripheral blood tumor cells in mice. Therefore, PM has the potential to treat diffuse large B cell lymphoma.

Compared with the blank control group, the body weight of the tumor-bearing animals in each dose of PM group did not decrease significantly during the treatment process, and the animals were in good condition during the whole experiment, indicating that the PM is efficacious and safe.

Main purpose:

To further explore the safe and effective dose of purinostat mesylate for injection in the treatment of relapsed or refractory diffuse large B-cell lymphoma.

To evaluate the objective response rate (ORR) of purinostat mesylate for injection in the treatment of relapsed or refractory diffuse large B-cell lymphoma.

Secondary purpose:

To evaluate the time to tumor response (TTR), duration of response (DOR), disease control rate (DCR), and progression-free survival (PFS) in the treatment of relapsed or refractory diffuse large B-cell lymphoma with purinostat mesylate for injection ), overall survival (OS).

Assessing the safety and tolerability of purinostat mesylate for injection in the treatment of relapsed or refractory diffuse large B-cell lymphoma.

Exploratory purpose:

To explore the biomarkers related to the efficacy of purinostat mesylate for injection.

02

Conditions studied

  • Diffuse Large B Cell Lymphoma,DLBCL
03

In context

Lead sponsor

Chengdu Zenitar Biomedical Technology Co., Ltd is the lead sponsor of 24 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years, both males and females are eligible;
  2. confirmed diffuse large B-cell lymphoma (DLBCL) by tissue (including primary DLBCL and transformed DLBCL from indolent lymphoma; patients with relapse after more than one year require a repeat tissue biopsy to confirm the pathological diagnosis), and must be , specifically defined as: DLBCL patients who have received no more than 5 lines of prior systemic therapy. Relapse includes: 1) relapse occurring more than 6 months after the completion of therapy; 2) relapse occurring more than 3 months after sequential hematopoietic stem cell transplantation following second-line therapy. Refractory includes: 1) primary refractory to first-line standard therapy (i.e., no response to treatment or relapse within 6 months after treatment completion); 2) relapse within 6 months after second-line therapy or failure to achieve partial response (PR) after 2 or more cycles of second-line therapy, or progression during second-line therapy (no specific cycle requirement for refractory patients). Prior treatment must include anti-CD20 monoclonal antibody (unless ) and anthracycline-based chemotherapy (unless anthracycline is contraindicated). Anti-CD20 monoclonal antibody monotherapy for consolidation or induction does not count as a separate line of therapy. Prior stem cell transplantation is allowed; standalone stem cell transplantation does not count as a line of therapy, as induction, consolidation, stem cell collection, conditioning regimen, and transplantation ± maintenance therapy are considered one line of therapy.
  3. Presence of , defined as: lymph node lesions with the longest diameter > 15 mm or extranodal lesions with the longest diameter > 10 mm as measured by contrast-enhanced CT, MRI, or PET-CT; willingness to undergo bone marrow aspiration cytology and/or biopsy for efficacy evaluation if required.
  4. Prior to the first dose of study treatment, the following intervals must be observed: ≥ 4 weeks since the last systemic radiotherapy; ≥ 2 weeks since local radiotherapy or radiotherapy for bone ; no radiopharmaceuticals administered within 8 weeks prior to the first dose of study treatment; ≥ 3 weeks since the last chemotherapy or approved targeted therapy; biological therapy, immunotherapy, and other treatments must be completed at least 4 weeks prior to the first dose of study treatment.
  5. performance status (Appendix 1) ≤ 2;
  6. Expected survival > 12 weeks;
  7. Hematological parameters must meet the following criteria: a) (ANC) ≥ 1.0 × 10\^9/L; b) (HGB) ≥ 80 g/L; c) count (PLT) ≥ 75 × 10\^9/L, with no platelet or red blood cell transfusions within 2 weeks prior to screening. Note: If the investigator believes that the patient's laboratory values below the protocol limits are due to bone marrow involvement by lymphoma, the patient's eligibility may be determined after discussion with the sponsor and CRO medical team.
  8. Liver and kidney function test results must meet the following criteria: a) Serum total (TBiL) ≤ 1.5 × (ULN); b) (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) ≤ 2.5 × ULN; c) Serum creatinine ≤ 1.5 × ULN. Note: Patients with Gilbert's syndrome may be enrolled if TBiL ≤ 3.0 × ULN; patients with liver involvement by lymphoma may be enrolled if AST, ALT, and ALP ≤ 5 × ULN.
  9. (LVEF) ≥ 50% as measured by echocardiography;
  10. Women of and men must agree to use effective from the time of signing the form until 6 months after the last dose of pomalidomide mesylate. Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose. Women of childbearing potential include premenopausal women and women within 1 year of menopause.
  11. Participants must voluntarily sign the informed consent form, be able to communicate effectively with the investigator, and comply with the study visit schedule, treatment plan, laboratory tests, and other study procedures.

Exclusion criteria

Exclusion Criteria

  1. Subjects who meet any of the following criteria will be excluded from the trial:
  2. Known severe allergy to the drug or any of its ;
  3. Primary central nervous system lymphoma or lymphoma involving the central nervous system;
  4. Prior chronic lymphoma transformation (e.g., Richter syndrome, prolymphocytic leukemia, etc.);
  5. Presence of other active requiring treatment that may interfere with the study;
  6. History of solid organ or hematopoietic stem cell transplantation;
  7. Coagulation abnormalities, defined as: (INR) > 1.5 × (ULN), prothrombin time (PT) > 1.5 × ULN, activated partial thromboplastin time (APTT) > 1.5 × ULN, thrombin time (TT) > 1.5 × ULN, or fibrinogen (FIB) \< 1 g/L;
  8. Active infection with virus (HBV) or virus (HCV), except for the following:

    1. HBV infection: If hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) is positive, peripheral blood HBV DNA titer must be ≤ 1 × 10\^3 copies/mL for enrollment; antiviral therapy must be continued after enrollment, and HBV DNA titer must be monitored every cycle;
    2. HCV seropositivity with negative HCV RNA test results is allowed for enrollment; Positive antibody (HIV-Ab) or positive syphilis antibody (TP-Ab) (patients with positive syphilis antibody in phase IIb may undergo titer testing, and eligibility will be determined by the investigator based on comprehensive assessment);
  9. Any of the following cardiac function-related criteria:

    1. arrhythmias or conduction abnormalities requiring clinical intervention;
    2. Average interval (QTcF) > 450 msec (male) or > 470 msec (female) based on three (ECG) measurements (retesting is required only if the first ECG shows QTcF > 450 msec (male) or > 470 msec (female), and the average of three measurements will be used);
    3. History of long QT syndrome or confirmed family history of long QT syndrome; history of clinically significant ventricular arrhythmias, or current use of antiarrhythmic drugs or implanted defibrillator for ventricular arrhythmias;
    4. Clinically significant cardiovascular diseases, including acute myocardial infarction, unstable angina, coronary artery bypass grafting, or cardiomyopathy within 6 months prior to the first dose; congestive heart failure classified as (NYHA) class 3 or higher, or (LVEF) \< 50%;
  10. Other systemic diseases:

    1. Poorly controlled diabetes;
    2. Severe pulmonary disease ( V5.0 grade III-IV);
    3. History of psychiatric disorders, family history of psychiatric disorders, or mood disorders as judged by the investigator or psychiatrist, including medical records of depressive episodes, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, suicide attempts or suicidal ideation, or homicidal thoughts (immediate risk of harm to others), or anxiety of grade 3 or higher;
  11. Prior treatment conditions:

    1. Chimeric antigen receptor T-cell immunotherapy (CAR-T therapy) within 3 months prior to the first dose;
    2. Prior treatment with HDAC inhibitors (except for chidamide) or other small molecule targeted therapies;
    3. Autologous hematopoietic stem cell transplantation within 3 months prior to the first dose;
    4. Radiotherapy affecting the efficacy evaluation of this study or local radiotherapy affecting bone marrow function within 3 months prior to the first dose;
    5. Myelosuppressive chemotherapy, biological therapy, or targeted therapy within 4 weeks prior to the first dose;
    6. Major surgery (excluding tumor ) within 4 weeks prior to the first dose, or if the patient has not recovered or the side effects of surgery have not stabilized;
    7. Treatment with hematopoietic growth factors (e.g., granulocyte colony-stimulating factor [G-CSF], granulocyte-macrophage colony-stimulating factor [GM-CSF]), recombinant IL-11, thrombopoietin, or TPO-R agonists within 2 weeks prior to the first dose. Note: Subjects who started erythropoietin or darbepoetin treatment within 2 weeks prior to the first dose are eligible;
    8. Treatment with prednisone > 10 mg daily (or equivalent doses of other , see Appendix 2) within 7 days prior to the first dose. Note: If used for non-lymphoma conditions such as rheumatoid arthritis, polymyalgia rheumatica, adrenal insufficiency, or asthma, subjects may receive a stable dose of prednisone up to 10 mg daily (or equivalent doses of other glucocorticoids);
  12. Persistent grade 2 or higher toxicities (CTCAE V5.0 criteria) from prior treatment (chemotherapy, biological therapy, or targeted therapy) that have not recovered to ≤ grade 1 at the time of enrollment (excluding alopecia);
  13. Uncontrolled active clinical infections of grade 2 or higher (CTCAE V5.0 criteria) requiring systemic anti-infective therapy (except if the infection is controlled but maintenance anti-infective therapy is still required);
  14. Treatment within 7 days prior to the first dose with: known strong inhibitors/inducers or drugs known to significantly prolong the QT interval (concomitant use of weak CYP3A4 inhibitors is allowed; see Appendix 3 for a list of common CYP3A4 inhibitors or inducers);
  15. Participation in other interventional clinical trials within 4 weeks prior to the first dose;
  16. Pregnant or breastfeeding women;
  17. Alcohol or drug abusers;
  18. Conditions that, in the investigator's judgment, may compromise the subject's safety or compliance;
  19. Subjects deemed unsuitable for participation in this trial by the investigator.
Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    Purinostat Mesylate for Injection 8.4mg/m^2

    The medication is administered once via intravenous infusion on days 1, 4, 8, and 11 of each 21-day treatment cycle.

    Drug: PM 8.4 mg/m^2

  • Experimental
    Purinostat Mesylate for Injection 11.2mg/m^2

    The medication is administered once via intravenous infusion on days 1, 4, 8, and 11 of each 21-day treatment cycle.

    Drug: PM 11.2 mg/m^2

Interventions

  • DrugPM 8.4 mg/m^2

    The medication is administered once via intravenous infusion on days 1, 4, 8, and 11 of each 21-day treatment cycle. A total of 6 cycles are planned, with tumor response assessments performed every 2 cycles during the treatment period.

  • DrugPM 11.2 mg/m^2

    The medication is administered once via intravenous infusion on days 1, 4, 8, and 11 of each 21-day treatment cycle. A total of 6 cycles are planned, with tumor response assessments performed every 2 cycles during the treatment period.

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR) of PM

    proportion of patients whose tumors have shrunk to the pre-specified value and maintained for required minimum time,including CR and PR.

    Time frame: each cycle lasts 21 days, and patients are assessed every 2 cycles until maximum of 2 years.

Secondary outcomes

  1. TTR

    The time between the first treatment and the first objective response

    Time frame: each cycle lasts 21 days, and patients are assessed every 2 cycles until maximum of 2 years.

  2. Duration of relief (DOR) of PM

    The time from the first documentation of complete remission (CR) or partial remission (PR) to the first documentation of disease progression (PD)

    Time frame: each cycle lasts 21 days, and patients are assessed every 2 cycles until maximum of 2 years.

  3. Overall survival (OS) of PM

    Time from the patient's first administration of Purinostat Mesylate for Injection to death from any cause.

    Time frame: each cycle lasts 21 days, and patients are assessed every 2 cycles until maximum of 2 years.

  4. Progression-free survival (PFS) of PM

    Time from the patient's first administration of Purinostat Mesylate for Injection to the occurrence of disease progression (PD) or death, whichever occurs first.

    Time frame: each cycle lasts 21 days, and patients are assessed every 2 cycles until maximum of 2 years.

  5. Disease control rate (DCR) of PM

    proportion of patients whose tumors have shrunk or remained stable for a certain period of time, including CR, PR and SD (stable disease) cases

    Time frame: each cycle lasts 21 days, and patients are assessed every 2 cycles until maximum of 2 years.

07

Study locations

2 sites
  • Ruijin Hospital of Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality 200025, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2022 (actual). Primary completion is estimated for Dec 2026, 49 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2022
First posted
Oct 3, 2022
StartActual
Nov 8, 2022
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 1, 2027
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05563844
Responsible party
Sponsor
First posted
Oct 3, 2022
Start date
Nov 8, 2022
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Feb 4, 2026

Study contacts

Ting Niu, Doctor
principal investigator · West China Hospital
Weili Zhao, Doctor
principal investigator · Ruijin Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion